|
Back to Home » September 2019 News » Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed |
Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed |
September 27, 2019
STOCKHOLM, Sept. 26, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the last patient has been included in the OP-106 HORIZON pivotal phase 2 clinical study evaluating melflufen with dexamethasone in patients with relapsed/refractory multiple myeloma...
Source URL: https://www.prnewswire.com:443/news-releases/patient-recruitment-in-the-pivotal-phase-2-study-horizon-completed-300926147.html
|
|
|
|
